LM-317

LM-317: sourced facts only. name: "LM-317 is a novel NaPi2b targeted humanized monoclonal antibody LM-117 conjugated to the next-generation topoisomerase I inhibitor LDX2 via a cleavable linker, with antibody-drug ratio of 8." [DOI:10.1158/1538-7445.am2024-5907]; target: "LM-317 is a novel NaPi2b targeted humanized monoclonal antibody LM-117 conjugated to the next-generation topoisomerase I inhibitor LDX2 via a cleavable linker, with antibody-drug ratio of 8." [DOI:10.1158/1538-7445.am2024-5907]; developer: "1LaNova Medicines Limited, Shanghai, China." [DOI:10.1158/1538-7445.am2024-5907]; modality: "The novel ADC LM-317 targeting NaPi2b showed robust antitumor activity in vitro, and in the OC and NSCLC cell line derived models and PDX models." [DOI:10.1158/1538-7445.am2024-5907]; stage: "The in vivo studies showed that 1 mg/kg of LM-317 almost completely eradicated tumors in the OVCAR-3 xenograft mice model of OC, and similar antitumor activity was observed in the NCI-H175-xenograft mice model of NSCLC at the dose of 3 mg/kg." [DOI:10.1158/1538-7445.am2024-5907]